OYE Therapeutics Administers First Patient Dose in 505(b)(2) Bridging Study for OYE-101

OYE Therapeutics Inc., a clinical-stage biotechnology company, has administered the first patient dose in its 505(b)(2) bridging study for OYE-101. The study marks a significant step in the development of treatments aimed at addressing critical needs in perioperative and emergency medicine. The company is conducting this research from its base at the Purdue Technology Center within the Purdue Research Park of Northwest Indiana.

The 505(b)(2) regulatory pathway allows for streamlined drug approval by leveraging existing data on previously approved drugs, potentially accelerating the development process. OYE Therapeutics’ bridging study seeks to evaluate OYE-101’s safety and efficacy while building on prior scientific findings. This milestone represents progress in advancing therapeutic options for patients facing urgent medical conditions. Further details regarding the study’s scope and timeline have not been disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI